Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples